Category - Markets

Ladenburg Thalmann initiated coverage of Flex Pharma (NASDAQ:FLKS) with a “buy” rating and $12 price target. The stock closed at $4.02 on Jan. 24. Flex is leveraging its research in muscle cramping as a disorder of...

Canaccord Genuity resumed coverage of Neovasc (NASDAQ:NVCN) with a “buy” rating and price target of $1.05. The stock closed at 53 cents on Jan. 18. Analyst Jason Mills writes that Neovasc recently reported acceleration...

Mackie Research Capital resumed coverage of WeedMD (TSXV:WMD) and raised its price target to $4 from $3 after the company completed a $34.5-million offering of units. The stock closed at $2.60 on Jan. 16. WeedMD is a...

Ladenburg Thalmann downgraded Aradigm (NASDAQ:ARDM) to “neutral” from “buy” and removed its previous $10 price target. The stock closed at $3.42 on Jan. 16. On Jan 11, the Antimicrobial Drugs Advisory Committee of the...

William Blair initiated coverage of Pieris Pharmaceuticals (NASDAQ:PIRS) with an “outperform” rating. The stock closed $7.46 on Jan. 16. Analyst Matthew Phipps writes that the company’s Anticalin platform continues to...

For 2018, CIBC World Markets is recommending investors hold a basket of healthcare stocks that include a combination of more speculative small and midcap companies with selected large caps. Analyst Prakash Gowd writes...

Maxim Group launched coverage of Immune Pharmaceuticals (NASDAQ:IMNP) with a “buy” rating and $3 price target. The stock closed at 57 cents on Jan. 4. Immune’s bertilimumab is a monoclonal antibody (mAb), targeting...

Leerink initiated coverage on Regulus Therapeutics (NASDAQ:RGLS) with an “outperform” rating and 12-month price target of $2. The stock closed at $1.18 on Jan. 4. “We believe that following numerous clinical setbacks...

Ladenburg Thalmann initiated coverage of UroGen Pharma (NASDAQ:URGN) with a “buy” rating and $50 price target. The stock closed at $37.21 on Dec. 29. UroGen is developing RTGel, a reverse, thermally-triggered hydrogel...

Roth Capital Partners launched coverage of Genfit (PSE:GNFT) with a “buy” rating and 12-month price target of €116. The stock closed at €22.09 on Dec. 20. “A spearhead in NASH drug development, Paris-based Genfit is...